Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
| ▸ | SDCBP | O00560 | 1/20 | 0.34 |
| ▸ | SDC2 | P34741 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24642846 | 0.95 | CAPN1 (0.39) | CA2CA1TDP1ATMMEN1 | |
| SCHEMBL24642859 | 0.89 | TDP1 (0.36) | CA2CA1TDP1ATMMAPT | |
| SCHEMBL24642833 | 0.84 | MMP2 (0.33) | ITGB1ITGA4 | |
| SCHEMBL30604911 | 0.82 | MMP2 (0.32) | CA2CA1 | |
| SCHEMBL24642682 | 0.82 | MMP2 (0.32) | — | |
| SCHEMBL26528748 | 0.82 | NOD1 (0.32) | — | |
| SCHEMBL31538101 | 0.81 | GLP1R (0.39) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL26527755 | 0.81 | GLP1R (0.39) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL26528590 | 0.81 | TDP1 (0.40) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL30604905 | 0.81 | GLP1R (0.39) | TDP1ATMMAPTNPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748843-A2 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4556026-A1 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| EP-4552654-A1 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-05-14 | — | — | EP | disclosed |
| US-20250144229-A1 | CONJUGATE OF ANTIBODY-ERIBULIN OR DERIVATIVE THEREOF, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| EP-4480499-A1 | CONJUGATE OF ANTIBODY-ERIBULIN OR DERIVATIVE THEREOF, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2024-12-25 | — | — | EP | disclosed |
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022170971-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州宜联生物医药有限公司 | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144229-A1 | CONJUGATE OF ANTIBODY-ERIBULIN OR DERIVATIVE THEREOF, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | ERLIN1, WEE1, ERLIN2 | CA2 4367/4885CA1 2573/4885TDP1 3976/4885 |
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | CTSL, VIP, FURIN | CA2 4620/4885CA1 3250/4885TDP1 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.